A Multicentre Randomized Double-Blind Placebo-Controlled Phase III Study of the Efficacy and Safety of Xeligekimab (GR1501) in Patients with Moderate-to-severe Plaque Psoriasis

Lin Cai,Congjun Jiang,Guoqiang Zhang,Hong Fang,Jinyan Wang,Yumei Li,Hui Xu,Rong Xiao,Yangfeng Ding,Kun Huang,Chunlei Zhang,Litao Zhang,Bin Chen,Xinsuo Duan,Weili Pan,Guangming Han,Rongyi Chen,Lunfei Liu,Shoumin Zhang,Juan Tao,Xiaowen Pang,Jianbin Yu,Huiping Wang,Yi Zhao,Chengxin Li,Xiaojing Kang,Lanying Qin,Xiaofang Zhu,Juan Su,Shanshan Li,Chunjun Yang,Wenli Feng,Tiechi Lei,Shan Jiang,Ruihua Fang,Mao Lin,Qianjin Lu,Chunxing Xu,Wei Wang,Jianzhong Zhang

DOI: https://doi.org/10.1093/bjd/ljae062

IF: 11.113

2024-01-01

British Journal of Dermatology

Abstract:Background Xeligekimab (GR1501) is a fully human monoclonal antibody that selectively neutralizes interleukin (IL)-17A and has shown potential efficacy in treating moderate-to-severe psoriasis in preliminary trials.Objectives To evaluate the efficacy and safety of xeligekimab in Chinese patients with moderate-to-severe psoriasis.Methods A total of 420 Chinese patients were randomized to 200 mg xeligekimab every 2 weeks (n = 281) or placebo (n = 139) for the first 12 weeks, followed by an extension of the treatment schedule to xeligekimab every 4 weeks for a further 40 weeks. Efficacy was assessed by evaluating achievement of Physician Global Assessment (PGA) 0/1 and 75%, 90% and 100% improvement in Psoriasis Area and Severity Index (PASI 75, PASI 90 and PASI 100, respectively). The safety profile was also evaluated.Results At week 12, PASI 75, PASI 90 and PASI 100 were achieved in 90.7%, 74.4% and 30.2% of patients in the xeligekimab group vs. 8.6%, 1.4% and 0% of patients in the placebo group, respectively. PGA 0/1 was achieved in 74.4% patients in the xeligekimab group and 3.6% of patients in the placebo group. PASI 75 and PGA 0/1 were maintained until week 52. No unexpected adverse events were recorded.Conclusions Xeligekimab showed high efficacy and was well tolerated in Chinese patients with moderate-to-severe plaque psoriasis. Xeligekimab, a recombinant all-human IgG4 anti-IL-17A monoclonal antibody drug, showed superior efficacy regardless of rapid clearance of lesions or long-term stable remission of moderate-to-severe plaque psoriasis. Xeligekimab was well-tolerated, with no unexpected adverse effects in Chinese patients. Psoriasis is a skin disease characterized by scaly and raised patches of skin on any part of the body. The condition can be caused by a combination of how a person's immune system works, their genes and their environment. A cytokine is a substance secreted by certain cells of the immune system that have an effect on other cells. One such cytokine, called IL-17A, has been associated with different inflammatory diseases, including psoriasis.We conducted a large trial in Chinese people with moderate-to-severe psoriasis to look at the efficacy (ability to produce the intended result) and safety of a medicine called xeligekimab (known as a 'monoclonal antibody') which works by targeting IL-17A. We randomly assigned 420 Chinese patients to receive 200 mg of xeligekimab every 2 weeks or a 'placebo' (no active medicine) for the first 12 weeks. We extended the treatment schedule of xeligekimab to every 4 weeks for a further 40 weeks. To assess how the medicine worked, we measured people's psoriasis symptoms and severity. To assess how safe the medicine was, we looked at the side-effects (or 'adverse events').The results of this trial showed that xeligekimab improved people's psoriasis and itching starting at week 4 of receiving treatment, and more than 60% of people achieved improvement or remission by week 6, which was sustained up to week 52.The safety of xeligekimab was similar to another medicine classed as a monoclonal antibody (called secukinumab) and there were no new or unexpected adverse events reported.Overall, our findings suggest that xeligekimab is a safe and effective medicine for the treatment of psoriasis in Chinese people.